CEL-SCI CORPORATION Revenue Breakdown
No Revenue Breakdown for CVM on this site yet.
- 2014-09-30: Total revenue $264.03K.
- 2013-09-30: Total revenue $159.58K.
- 2012-09-30: Total revenue $254.61K.
- 2011-09-30: Others Not split by product in the filing$956.15K100.00%; Total revenue $956.15K.
Source checked: the stored Revenue Breakdown page for CVM.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2014-09-30 | $264.03K | |
| 2013-09-30 | $159.58K | |
| 2012-09-30 | $254.61K | |
| 2011-09-30 | Not split by product in the filing $956.15K 100.00% | $956.15K |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2017-06-30 | Not split by product $17.39K 100.00% | $17.39K |
| 2016-06-30 | Not split by product $129.97K 100.00% | $129.97K |
| 2014-09-30 | Not split by product $67.82K 100.00% | $67.82K |
| 2014-06-30 | Not split by product $15.91K 100.00% | $15.91K |
| 2014-03-31 | Not split by product $67.16K 100.00% | $67.16K |
| 2013-12-31 | Not split by product $113.14K 100.00% | $113.14K |
| 2013-09-30 | Not split by product $15.45K 100.00% | $15.45K |
| 2013-06-30 | Not split by product $113.73K 100.00% | $113.73K |
| 2013-03-31 | Not split by product $15.40K 100.00% | $15.40K |
| 2012-12-31 | Not split by product $15.00K 100.00% | $15.00K |
| 2012-09-30 | Not split by product $108.04K 100.00% | $108.04K |
| 2012-06-30 | Not split by product $35.00K 100.00% | $35.00K |
| 2012-03-31 | Not split by product $106.54K 100.00% | $106.54K |
| 2011-12-31 | Not split by product $5.02K 100.00% | $5.02K |
| 2011-09-30 | Not split by product $172.12K 100.00% | $172.12K |
| 2011-06-30 | Not split by product $77.40K 100.00% | $77.40K |
| 2011-03-31 | Not split by product $43.81K 100.00% | $43.81K |
| 2010-12-31 | Not split by product $662.82K 100.00% | $662.82K |
| 2010-06-30 | Not split by product $30.90K 100.00% | $30.90K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |